UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020543
Receipt number R000023718
Scientific Title Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis
Date of disclosure of the study information 2016/01/13
Last modified on 2019/01/29 13:14:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Acronym

Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Scientific Title

Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Scientific Title:Acronym

Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Region

Japan


Condition

Condition

pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Classification by specialty

Cardiology Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of imatinib for patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Efficacy (Time to clinical worsening)

Key secondary outcomes

Safety
Efficacy (Median survival)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral administration of imatinib

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who are diagnosed with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis and treated at the principal investigator's institution
Patients who are 18 years or older at the time of giving their written consent

Key exclusion criteria

Patients with a contraindication to imatinib
Patients who were considered as inadequate for enrollment by the principal investigator

Target sample size

8


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiromi Matsubara

Organization

National Hospital Organization Okayama Medical Center

Division name

Departments of Cardiology and Clinical Science

Zip code


Address

1711-1 Tamasu, Kita-ku, Okayama, JAPAN

TEL

086-294-9911

Email

himatsu@okayamamc.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiromi Matsubara

Organization

National Hospital Organization Okayama Medical Center

Division name

Departments of Cardiology and Clinical Science

Zip code


Address

1711-1 Tamasu, Kita-ku, Okayama, JAPAN

TEL

086-294-9911

Homepage URL


Email

himatsu@okayamamc.jp


Sponsor or person

Institute

National Hospital Organization Okayama Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 01 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2015 Year 02 Month 05 Day

Date of IRB


Anticipated trial start date

2015 Year 03 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 01 Month 13 Day

Last modified on

2019 Year 01 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023718


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name